A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder

Health Technology Assessment

Volumn 11, Issue 39, 2007, Pages

  Soares Weiser, K ^a   Vergel, Y Bravo ^a   Beynon, S ^a   Dunn, G ^a   Barbieri, M ^b   Duffy, S ^a   Geddes, J ^c   Gilbody, S ^a   Palmer, S ^a   Woolacott, N ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CARBAMAZEPINE; FLUPENTIXOL; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; VALPROATE SEMISODIUM; VALPROIC ACID; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; TRANQUILIZER; TRIAZINE DERIVATIVE;

ACCIDENTAL INJURY; ADJUVANT THERAPY; AKATHISIA; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; CRISIS INTERVENTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; FAMILY THERAPY; GASTROINTESTINAL TOXICITY; GROUP THERAPY; HEALTH CARE COST; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; MORTALITY; NATIONAL HEALTH SERVICE; OUTCOME ASSESSMENT; PARKINSONISM; PSYCHOEDUCATION; PSYCHOLOGICAL RATING SCALE; PSYCHOSOCIAL CARE; RELAPSE; REVIEW; RISK REDUCTION; SEDATION; SIDE EFFECT; SUICIDE; SYSTEMATIC REVIEW; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; ADULT; BIBLIOGRAPHIC DATABASE; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIPOLAR DISORDER; CARBAMAZEPINE; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DATABASES, BIBLIOGRAPHIC; FEMALE; HUMANS; LITHIUM; MALE; MODELS, ECONOMIC; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; TRIAZINES; VALPROIC ACID;

EID: 40549107168     PISSN: 13665278     EISSN: None     Source Type: Journal    
DOI: 10.3310/hta11390     Document Type: Review

References (122)

1. Muller-Oerlinghausen B, Berghofer A, Bauer M. Bipolar disorder. Lancet 2002;359:241-47
2. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349:1436-42.
3. Belmaker RH. Bipolar disorder. N Engl J Med 2004; 351:476-86.
4. Burgess S, Geddes J, Hawton K, Townsend E, Jamison K, Goodwin G. Lithium for maintenance treatment of mood disorders. Cochrane Database Syst Rev 2001;(3):CD003013.
5. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:149-73.
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 2000.
7. Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60:261-9.
8. Judd L, Akiskal HS, Schettler P, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:531-7.
9. Angst J, Sellaro R. Historical perspectives and natural history of bipolar disorder. Biol Psychiatry 2000;48:445-57.
10. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005;66 Suppl 5:5-10.
11. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord 2001;3:181-88
12. Goodwin GM, Geddes JR. Latest maintenance data on lithium in bipolar disorder. Eur Neuropsychopharmacol 2003;13 Suppl 2:S51-5.
13. Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization. Am J Psychiatry 2002; 159:1927-29.
14. Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry 2002; 180:227-33.
15. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002;63:5-12
16. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005;66 Suppl 5:11-16.
17. Grunze H. Reevaluating therapies for bipolar depression. J Clin Psychiatry 2005;66 Suppl 5:17-25.
18. Keck PE Jr, McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry 2002;63 Suppl 10:13-17
19. Ghaemi SN, Pardo TB, Hsu DJ. Strategies for preventing the recurrence of bipolar disorder. J Clin. Psychiatry 2004;65 Suppl 10:16-23.
20. Kusumakar V. Antidepressants and antipsychotics in the long-term treatment of bipolar disorder. J Clin Psychiatry 2002;63 Suppl 10:23-8.
21. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004;12:14-41.
22. Nemeroff CB. Safety of available agents used to treat bipolar disorder: focus on weight gain. J Clin Psychiatry 2003;64:532-39.
23. Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003;5 Suppl 2:7-19.
24. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
25. Vieta E, Colom F. Psychological interventions in bipolar disorder: from wishful thinking to an evidence-based approach. Acta Psychiatr Scand Suppl 2004;110:34-8.
26. Vieta E. The package of care for patients with bipolar depression. J Clin Psychiatry 2005; 66 Suppl 5:34-9.
27. Scott J. Cognitive therapy as an adjunct to medication in bipolar disorder. Br J Psychiatry 2001;178:S164-8.
28. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disorder. Psychiatr Serv 2004; 55:264-9.
29. National Collaborating Centre for Mental Health, Commissioned by the National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. Full guideline. July 2006 [monograph online]. London: National Institute for Health and Clinical Excellence; 2006. URL: http://www.nice.org.uk/page.aspx?o=290516
30. NHS Centre for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD's guidance for carrying out or commissioning reviews. CRD Report 4. 2nd ed. York: University of York; 2001.
31. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. Chichester: Wiley; 2005.
32. Gamble C, Hollis S. Uncertainty method improved on best-worst case analysis in a binary meta-analysis. J Clin Epidemiol 2005; 58:579-88.
33. Decks JJ, Higgins JPT, Altman DG. Analysing and presenting results. In: Alderson P, Green S, Higgins JPT, editors. Cochrane reviewers' handbook 4.2 [updated December 2003]; Section 8. Cochrane Library, Issue 1, 2004. Chichester: Wiley; 2004.
34. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.
35. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105-24.
36. Findling RL, McNamara NK, Youngstrom EA, Stansbrey R, Gracious BL, Reed MD, et al. Double-blind 18-month trial of lithium versus divalproex maintenance treatment in pediatric bipolar disorder. J Am Acad child Adolesc Psychiatry 2005; 44:409-17.
37. Altamura AC, Salvadori D, Madaro D, Santini A, Mundo E. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord 2003;76:267-71.
38. Altamura AC, Russo M, Vismara S, Mundo E. Comparative evaluation of olanzapine efficacy in the maintenance treatment of bipolar disorder. J Clin Psychopharmacol 2004;24:454-6.
39. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
40. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60:392-400.
41. Calabrese JR, Suppes T, Bowden CL, Sachs GS, Swann AC, McElroy SL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000; 61:841-50.
42. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen OP, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003;64: 1013-24.
43. Calabrese JR, Shelton MD, Rapport DJ, Youngstrom EA, Jackson K, Bilali S, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152-61
44. Cochran SD. Preventing medical noncompliance in the outpatient treatment of bipolar affective disorders. J Consult Clin Psychol 1984; 52:873-8.
45. Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry 2003a;60:402-7.
46. Colom F, Vieta E, Reinares M, Martinez-Aran A, Torrent C, Goikolea JM, et al. Psychoeducation efficacy in bipolar disorders: beyond compliance enhancement. J Clin Psychiatry 2003b;64:1101-5.
47. Coxhead N, Silverstone T, Cookson J. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand 1992;85:114-18.
48. Dunner DL, Stallone F, Fieve RR. Lithium carbonate and affective disorders. V: a double-blind study of prophylaxis of depression in bipolar illness. Arch Gen Psychiatry 1976;33:117-20.
49. Esparon J, Kolloori J, Naylor GJ, McHarg AM, Smith AH, Hopwood SE. Comparison of the prophylactic action of flupenthixol with placebo in lithium treated manic-depressive patients. Br J Psychiatry 1986; 148:723-5.
50. Fieve RR, Kumbaraci T, Dunner DL. Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients. Am J Psychiatry 1976; 133:925-9.
51. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002; 63:442-6.
52. Gelenberg AJ, Kane JM, Keller MB, Lavori P, Rosenbaum JF, Cole K, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321:1489-93.
53. Hartong EG, Moleman P, Hoogduin CA, Broekman TG, Nolen WA, LitCar G. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64: 144-51.
54. Johnstone EC, Owens DG, Lambert MT, Crow TJ, Frith CD, Done DJ. Combination tricyclic antidepressant and lithium maintenance medication in unipolar and bipolar depressed patients. J Affect Disord 1990;20:225-33.
55. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Saraf K, Howard A, et al. Prophylactic lithium with and without imipramine for bipolar I patients: a double-blind study [meeting abstract]. Psychopharmacol Bull 1981;17:144-5.
56. Kane JM, Quitkin FM, Rifkin A, Ramos-Lorenzi JR, Nayak DD, Howard A. Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison. Arch Gen Psychiatry 1982;39: 1065-9.
57. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000;42 Suppl 1:2-10.
58. Lam DH, Bright J, Jones S, Hayward P, Schuck N, Chisholm D, et al. Cognitive therapy for bipolar illness: a pilot study of relapse prevention. Cognit Ther Res 2000;24:508-20.
59. Lam DH, Hayward P, Watkins ER, Wright K, Sham P. Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years. Am J Psychiatry 2005;162:324-9.
60. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153:198-204.
61. Maj M, Starace F, Nolfe G, Kemali D. Minimum plasma lithium levels required for effective prophylaxis in DSM III bipolar disorder: a prospective study. Pharmacopsychiatry 1986; 19:420-3.
62. Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry 2003; 60:904-12.
63. Perry A, Tarrier N, Morriss R, McCarthy E, Limb K. Randomised controlled trial of efficacy of teaching patients with bipolar disorder to identify early symptoms of relapse and obtain treatment. BMJ 1999; 318:149-53.
64. Platman SR. Comparison of lithium carbonate and imipramine: (in prevention of manic-depressive disease). Dis Nerv Syst 1970; 31:132-4.
65. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-5.
66. Prien RF, Caffey EM Jr, Klett CJ. Factors associated with treatment success in lithium carbonate prophylaxis. Report of the Veterans Administration and National Institute of Mental Health collaborative study group. Arch Gen Psychiatry 1974;31:189-92.
67. Prien RF, Kupfer DJ, Mansky PA, Small JG, Tuason VB, Voss GB, et al. Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 1984; 41:1096-104.
68. Rea MM, Tompson MC, Miklowitz DJ, Goldstein MJ, Hwang S, Mintz J. Family-focused treatment versus individual treatment for bipolar disorder: results of a randomized clinical trial. J Consult Clin Psychol 2003;71:482-92.
69. Revicki DA, Hirschfeld RM, Ahearn EP, Weisler RH, Palmer C, Keck PE Jr. Effectiveness and medical costs of divalproex versus lithium in the treatment of bipolar disorder: results of a naturalistic clinical trial. J Affect Disord 2005; 86:183-93.
70. Scott J, Garland A, Moorhead S. A pilot study of cognitive therapy in bipolar disorders. Psychol Med 2001;31:459-67.
71. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P. Cognitive behaviour therapy for severe and recurrent bipolar disorders: a randomised controlled trial. Bipolar Disord 2005; 7:97.
72. Simhandl C, Denk E, Thau K. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord 1993;28:221-31.
73. Simon GE, Ludman EJ, Unutzer J, Bauer MS, Operskalski B, Rutter C. Randomized trial of a population-based care program for people with bipolar disorder. Psychol Med 2005;35:13-24.
74. Solomon DA, Ryan CE, Keitner GI, Miller IW, Shea MT, Kazim A, et al. A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder. J Clin Psychiatry 1997;58:95-9.
75. Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160: 1263-71.
76. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004; 184:337-45.
77. Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162:1281-90.
78. Tohen M, Calabrese JR, Sachs GS, Banov MD, Detke HC, Risser R, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006;163:247-56.
79. Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, et al. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry 2000; 61:361-7.
80. Zarate CA Jr, Tohen M. Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients. Am J Psychiatry 2004;161:169-71.
81. Scott J, Paykel E, Morriss R, Bentall R, Kinderman P, Johnson T, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006; 188:313-20.
82. Higgins JPT, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996; 15:2733-49.
83. Spiegelhalter DJ, Thomas A, Best NG, Lunn D. WinBUGS user manual: version 1.4. Cambridge: MRC Biostatistics Unit; 2001.
84. Revicki DA, Hanlon J, Martin S, Gyulai L, Ghaemi SN, Lynch F, et al. Patient-based utilities for bipolar disorder-related health states. J Affect Disord 2005;78:203-10.
85. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. J Affect Disord 1998; 48:25-36.
86. Kessing LV, Olsen EW, Andersen PK. Recurrence in affective disorder: analyses with frailty models. Am J Epidemiol 1999; 149:404-11.
87. Kessing LV, Sondergard L, Kvist K, Andersen PK. Suicide risk in patients treated with lithium. Arch Gen Psychiatry 2005;62:860-6.
88. Chisholm D, van Ommeren M, Ayuso-Mateos JL, Saxena S. Cost-effectiveness of clinical interventions for reducing the global burden of bipolar disorder. Br J Psychiatry 2005;187:559-67.
89. Baldessarini RJ, Tondo L, Hennen J. Treating the suicidal patient with bipolar disorder: reducing suicide risk with lithium. Ann N Y Acad Sci 2001; 932:24-38.
90. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998;173:11-53.
91. Keck PE, Jr., Nabulsi AA, Taylor JL, Henke CJ, Chmiel JJ, Stanton SP, et al. A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder. J Clin Psychiatry 1996;57:213-22.
92. Frye MA, Altshuler LL, Szuba MP, Finch NN, Mintz J. The relationship between antimanic agent for treatment of classic or dysphoric mania and length of hospital stay. J Clin Psychiatry 1996; 57:17-21.
93. Ferri C, Chisholm D, Van Ommeren M, Prince M. Resource utilisation for neuropsychiatric disorders in developing countries: a multinational Delphi consensus study. Soc Psychiatry Psychiatr Epidemiol 2004; 39:218-27.
94. Lam DH, McCrone P, Wright K, Kerr N. Cost-effectiveness of relapse-prevention cognitive therapy for bipolar disorder: 30-month study. Br J Psychiatry 2005;186:500-6.
95. First MB, Spitzer RL, Gibbon M. Structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. New York: Biometrics Research Department, New York State Psychiatric Institute; 1996.
96. Curtis L, Netten A. The unit costs of health and social care. 2005. Canterbury: University of Kent, Personal Social Services Research Unit; 2005.
97. Joint Formulary Committee. British National Formulary. 51st ed. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006. URL: www.BNF.org. Accessed March 2006.
98. Kupfer DJ, Frank E, Grochocinski VJ, Luther JF, Houck PR, Swartz HA, et al. Stabilization in the treatment of mania, depression and mixed states. Acta Neuropsychiatr 2000;12:110-14.
99. Kessing LV. Recurrence in affective disorder. II. Effect of age and gender. Br J Psychiatry 1998; 172:29-34.
100. Kessing LV, Andersen PK, Mortensen PB, Bolwig TG. Recurrence in affective disorder. I. Case register study. Br J Psychiatry 1998;172:23-8.
101. Calabrese J, Shelton M, Rapport D, Youngstrom E, Shirley E, Elhaj O, et al. A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling. Eur Neuropsychopharmacol 2003;13 Suppl 4:S227.
102. Department of Health. Hospital episode statistics, Vol 1. Finished consultant episodes by diagnosis, operation and specialty, England 2004-2005. London: Department of Health; 2005.
103. Hobbs FDR, Fitzmaurice DA, Mant J, Murray E, Jowett S, Bryan S, et al. A randomised control trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and ever. The SAFE study. Health Technol Assess 2005; 9(40).
104. Tsevat J, Keck PE, Hornung RW, McElroy SL. Health values of patients with bipolar disorder. Qual Life Res 2000;9:579-86.
105. Vojta C, Kinosian B, Glick H, Altshuler L, Bauer MS. Self-reported quality of life across mood states in bipolar disorder. Compr Psychiatry 2001;42:190-5.
106. Hayhurst H, Palmer S, Abbott R, Johnson T, Scott J. Measuring health-related quality of life in bipolar disorder: relationship of the EuroQol (EQ-5D) to condition-specific measures. Qual Life Res 2006;15: 1271-80.
107. Revicki DA, Paramore LC, Sommerville KW, Swann AC, Zajecka JM, Depakote Comparator Study G. Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes. J Clin Psychiatry 2003;64:288-94.
108. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-19.
109. Government Actuary's Department. Interim life tables 2002-2004 [monograph online]. 2005. URL: http://www.gad.gov.uk/Life_Tables/ Interim_life_tables.htm. Accessed March 2006.
110. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost effectiveness acceptability curves. Health Econ 2001; 10:779-89.
111. Raftery J. NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 2001;323: 1300-3.
112. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004; 161:217-22.
113. Geddes JR, Rendell JM. BALANCE 2: international trial of treatment for bipolar depression [meeting abstract]. Bipolar Disord 2005; 7:57.
114. Geddes JR, Rendell JM, on behalf of the BALANCE Investigators. Update on the progress of BALANCE [meeting abstract]. Bipolar Disord 2005; 7:58.
115. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001; (3):CD003196.
116. Department of Health. Best research for best health: a new national health research strategy: the NHS contribution to health research in England. London: Department of Health; 2006.
117. Cooksey D. A review of UK health research funding. London: Stationery Office; 2006.
118. Clement S, Singh SR, Burns T. Status of bipolar disorder research. Bibliometric study. Br J Psychiatry 2003;182:148-52.
119. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001;10:277-303.
120. Spiegelhalter DJ, Best NG, Carlin BR, van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc B 2002; 64:583-639.
121. Baldessarini RJ, Tondo L. Does lithium treatment still work? Evidence of stable responses over three decades. Arch Gen Psychiatry 2000; 57: 187-90.
122. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005;9: 279-300.